Only half a year after the foundation of the biotech company Lipocalyx, an important milestone of the demanding business plan could be reached successfully: The first proof of a new and promising drug delivery approach was delivered.

ChiroBlock, which took a strategical share in Lipocalyx, supports the company in providing sophisticated, new compounds which are part of Lipocalyx’ transfection system. After having passed this first critical milestone, both companies are confident to further make substantial progress within the next few months – resulting in a market entry of the new products by the year 2014.

Press Release 2011 – Collaboration Lipocalyx – ChiroBlock (german) (54 KB)